Biotech Values

[dewophile]

BMY - erbitux

it certainly never achieved blockbuster status, so probably did not meet internal thresholds. that said they got their money back on the equity side of the deal (i forget exactly what they paid but it was more or less what LLY bought the company for if i recall - so loss is in opportunity cost at most). so if they spent 1.5B (outside of equity), and they continue to reap 200M or so in profit annually (i could be off on this # but ballpark) it's not the worst deal in the world (this assumes of course no follow on compound comes along soon that hurts sales down the road)